Crescent Biopharma(DE:C68)
€11.00+0.40 (+3.77%)
DE:C68
Crescent Biopharma stock drug pipeline
€11.00
At close:+0.40 (+3.77%)
Crescent Biopharma (C68) Drug Pipeline
2 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Cr-001 | Locally Advanced / Metastatic Solid Tumors | phase1AndPhase2 | Not Yet Recruiting | CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors | Jan 08, 2026 | ― |
| Rivipansel | Anemia, Sickle Cell | Phase III | Completed | Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease | Jun 12, 2014 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Cr-001 | phase1AndPhase2 | Locally Advanced / Metastatic Solid Tumors | Not Yet Recruiting | CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors | Jan 08, 2026 | ― |
| Rivipansel | Phase III | Anemia, Sickle Cell | Completed | Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease | Jun 12, 2014 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Crescent Biopharma, Inc. (DE:C68) have in its pipeline
Crescent Biopharma DE:C68 is currently developing the following drugs: Cr-001, Rivipansel. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
